Iovance Biotherapeutics made $122 million in sales last quarter, which is 80% more than last year.

Nov 5, 2026, 9:27 AM ETResultsRead the original at Benzinga

Good for IOVA

Iovance reported record sales, growing AMTAGVI use, and cash expected to last into 2029. Its lung-cancer filing is only planned for 2027, but current business growth supports a positive read.

IOVA · Iovance Biotherapeutics

AI read · Good for IOVA

The AI's read

The expanding treatment-center network and more than 1,000 patients treated show AMTAGVI is reaching more people. Lung-cancer results showed a 24.6% response rate, compared with 12.8% for docetaxel, but these are still trial results. A filing is only planned for 2027. Current sales growth and the cash runway support the positive read before that possible expansion.

Get alerts for IOVA

Follow Iovance Biotherapeutics (IOVA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IOVA

Free on the App Store and Google Play, or on the web.